We have the evidence, we need to act to improve diabetes care

International Journal of Clinical Practice

Volumn 61, Issue SUPPL. 157, 2007, Pages 9-15

  Del Prato, S ^a,d   Horton, E ^b   Nesto, R ^c  

^a UNIVERSITY OF PISA   (Italy)

^b JOSLIN DIABETES CENTER   (United States)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^d CISANELLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIBENCLAMIDE; METFORMIN; PIOGLITAZONE; SULFONYLUREA; TROGLITAZONE;

DIABETES MELLITUS; GLYCEMIC CONTROL; HEALTH PROGRAM; HUMAN; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UNITED NATIONS;

EID: 35948986778     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01609.x     Document Type: Review

References (52)

1. Unite for Diabetes. A United Nations Resolution on Diabetes. http://www.unitefordiabetes.org/assets/files/UNR_overview.pdf (accessed August 2007).
2. Chan JM, Rimm EB, Colditz GA et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994 17 : 961 9.
3. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. Geneva, Switzerland : WHO, 2006.
4. Manuel DG, Schultz SE. Health-related quality of life and health-adjusted life expectancy of people with diabetes in Ontario, Canada, 1996-1997. Diabetes Care 2004 27 : 407 14.
5. United Nations. UN Resolution on Diabetes. Signed December 20, 2006. (UN Resolution 61/225). http://www.unitefordiabetes.org/campaign/resolution.html (accessed August 2007).
6. Bailey C, Del Prato S, Eddy D et al. Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control. Int J Clin Pract 2005 59 : 1309 16.
7. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004 88 : 787 835, ix.
8. Haffner SM, D'Agostino RJ, Mykkanen L et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999 22 : 562 8.
9. Bonora E, Kiechl S, Willeit J et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998 47 : 1643 9.
10. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2007 30 (Suppl. 1 S4 41.
11. Lindström J, Eriksson JG, Valle TT et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention study: results from a randomized clinical trial. J Am Soc Nephrol 2003 14 (Suppl. 2 S108 13.
12. Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997 20 : 537 44.
13. Zimmet PZ. Diabetes - definitions and classification. Med Int 1997 25 : 1 3.
14. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998 40 (Suppl. S21 5.
15. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991 34 : 877 90.
16. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 : 977 86.
17. Diabetes Control and Complications Trial Research Group, Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000 342 : 381 9.
18. Writing Team for the DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002 287 : 2563 9.
19. Martin CL, Albers J, Herman WH et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006 29 : 340 4.
20. Writing Team for the DCCT/EDIC Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. J Am Med Assoc 2003 290 : 2159 67.
21. Paterson AD, Rutledge BN, Cleary PA et al. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 2007 30 : 2107 12.
22. Nathan DM, Lachin J, Cleary P et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003 348 : 2294 303.
23. Cleary PA, Orchard TJ, Genuth S et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006 55 : 3556 65.
24. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353 : 2643 53.
25. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 28 : 103 17.
26. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
27. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 352 : 854 65.
28. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000 321 : 405 12.
29. Turner RC, Cull CA, Frighi V et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 1999 281 : 2005 12.
30. Kahn SE, Haffner S, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [erratum appears in N Engl J Med 2007; 356: 1387-8. N Engl J Med 2006 355 : 2427 43.
31. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003 27 (Suppl. 2 S1 152.
32. International Diabetes Federation Clinical Guidelines Taskforce. Global Guideline for Type 2 Diabetes, 2005. http://www.idf.org/webdata/docs/ IDF%20GGT2D.pdf (accessed August 2007).
33. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 29 : 1963 72.
34. Davidson JA, Blonde L, Jellinger PS et al. Road map for the prevention and treatment of type 2 diabetes. Endocr Pract 2006 12 (Suppl. 1 148 52.
35. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007 13 (Suppl. 1 1 68.
36. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. J Am Med Assoc 2004 291 : 335 42.
37. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002 45 : S23 8.
38. Resnick HE, Foster GL, Bardsley J et al. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006 29 : 531 7.
39. Calvert MJ, McManus RJ, Freemantle N. The management of people with type 2 diabetes with hypoglycaemic agents in primary care: retrospective cohort study. Fam Pract 2007 24 : 224 9.
40. Del Prato S, Felton A-M, Munro N et al. Improving glucose management: ten steps to get more patients with type 2 diabetes to goal. Recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract 2005 59 : 1345 55.
41. International Diabetes Federation. Diabetes Atlas, Third Edition, 2006. http://www.eatlas.idf.org/media/ (accessed August 2007).
42. Gillies CL, Abrams KR, Lambert PC et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. Br Med J 2007 334 : 299 302.
43. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 346 : 393 403.
44. Lindström J, Ilanne-Parikka P, Peltonen M et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006 368 : 1673 9.
45. Ramachandran A, Snehalatha C, Mary S et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006 49 : 289 97.
46. Chiasson JL, Josse RG, Gomis R et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002 359 : 2072 7.
47. Knowler WC, Hamman RF, Edelstein SL et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005 54 : 1150 6.
48. Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002 51 : 2796 803.
49. Xiang AH, Peters RK, Kjos SL et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in hispanic women with prior gestational diabetes. Diabetes 2006 55 : 517 22.
50. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 368 : 1096 105.
51. Nathan DM, Davidson MB, DeFronzo RA et al. ADA Consensus Statement: impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007 30 : 753 9.
52. Alberti KGMM, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med 2007 24 : 451 63.